Hims & Hers is expanding its weight-loss offering on its telehealth platform with the addition of Eli Lilly’s Zepbound ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

The company’s stock rise reflects investor optimism following the news that Hims & Hers will provide both branded versions of ...

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.